Sunnyvale,  CA 
United States
  • Booth: 3655

Translatable Neuroscience

High attrition rates in clinical trials is an indication that current testing is failing to predict safety/efficacy of compounds. NeuCyte supports the early phases of drug discovery programs as well as the investigation of MOAs for experimental compounds. Based on the SynFire® technology, our human neural invitro platforms are uniquely suited for assessing relevant higher order electrophysiology readouts which allow for a better predictor of drug efficacy and potential CNS Safety/Toxicology.

Send Email

Type your information and click "Send Email" to send an email to this exhibitor. To return to the previous screen without saving, click "Reset".